Clinical trials of the new thrombopoietin receptor agonists in the management of chemotherapy-induced thrombocytopenia are needed to address concerns about the safety and practical efficacy new agents before we accept them as standard therapies.
Mojibade N. Hassan
Advertisement
Articles by Mojibade N. Hassan
Advertisement
Latest Updated Articles
- Treating Chemotherapy-Induced Thrombocytopenia: Is It Time for Oncologists to Use Thrombopoietin Agonists?
Published: April 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
4
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
5
